Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period of August 2022. The filing serves to lodge the Company's annual statutory financial statements for the financial year ended June 30, 2022, as required by Australian law. The report was signed by Errol De Souza, Ph.D., Executive Chairman, on August 25, 2022.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing acts as a cover document referencing the full financial statements lodged with the Australian Securities Exchange (ASX) as Exhibit 99.2.
Material Changes
The filing text does not provide data to compare current period performance against prior periods. Material changes, if any, are contained within the referenced ASX Appendix 4E and statutory financial statements (Exhibit 99.2).
Guidance, Outlook, and Risks
The text does not include management commentary, future guidance, specific risk factors, or details on contingencies. These items are expected to be detailed in the attached press release (Exhibit 99.1) and the full statutory financial statements.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Neuphoria Therapeutics Inc.) and the filing registrant (Bionomics Limited).
- Review Exhibit 99.2 (ASX Appendix 4E) for the actual financial figures for the year ended June 30, 2022.
- Examine Exhibit 99.1 for the press release details regarding the annual results.
- Confirm the specific revenue and cash burn rates in the full statutory report, as they are absent from this summary text.